Key Points
July 6 (Reuters) - Novo Nordisk (NOVOb.CO) on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus...
In three separate lawsuits in Florida federal court, Novo Nordisk sought orders barring TruLife Pharmacy, Brooksville Pharmaceuticals and WellHealth Inc from selling the products, and seeking unspecified money damages..
It said that the pharmacies are selling new drugs without FDA approval and claiming to compete with Novo Nordisk's approved drugs, violating federal and state law...
Novo Nordisk said in the lawsuits that selling drugs without going through the FDA approval process gave the pharmacies an "unfair competitive advantage."..
The FDA in May warned in public guidance about the safety risks of unauthorized versions of Novo Nordisk's popular weight-loss drugs in response to reports of adverse health reactions to custom-made versions...
You might be interested in
Novo Nordisk, maker of Ozempic and Wegovy sues two pharmacies for ‘selling impure drugs’
30, Nov, 23Over alleged selling of contaminated drugs, two Florida-based pharmacies have been sued by Novo Nordisk. The company claims that the substance used for the production of the drugs does not have approval from the FDA.